Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tina Fox

Nurse Practitioner, Psychiatric/Mental Health Chattanooga, TN Nurse Practitioner

NPI 1760632434 CMS profile 10659014

6031 Shallowford Rd Ste 113, Chattanooga, TN 37421

Open in the dashboard

General payments

$14,331

750 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tina Fox of Chattanooga, TN is reported in the CMS Open Payments database as having received $14,331 across 750 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,643 177
2024 General $3,285 158
2023 General $3,094 160
2022 General $2,106 131
2021 General $2,203 124

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tina Fox
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Tina Fox were reported at $3,643. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Tina Fox Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,203 $166 $54–$482 $132
2022 $2,106 $195 $66–$559 $149
2023 $3,094 $233 $82–$673 $160
2024 $3,285 $236 $84–$688 $164
2025 $3,643 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Neurocrine Biosciences, Inc. $1,997 94 payments
  2. ITI, Inc. $1,395 71 payments
  3. Otsuka America Pharmaceutical, Inc. $1,188 106 payments
  4. Corium, Inc. $1,181 53 payments
  5. Supernus Pharmaceuticals, Inc. $1,148 43 payments
  6. AbbVie, Inc. $991 53 payments
  7. Alkermes, Inc. $972 41 payments
  8. Teva Pharmaceuticals USA, Inc. $821 42 payments
  9. Janssen Pharmaceuticals, Inc $700 40 payments
  10. Takeda Pharmaceuticals U.S.A., Inc. $553 36 payments
  11. Other $3,385 171 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $14,284 749 payments
  2. Education $47 1 payment
Products named General payments · program years 2021–2025
  1. INGREZZA $1,784 85 payments
  2. Azstarys $1,181 53 payments
  3. CAPLYTA $1,169 58 payments
  4. REXULTI $1,005 98 payments
  5. LYBALVI Cns $904 40 payments
  6. VRAYLAR $700 38 payments
  7. SPRAVATO $681 39 payments
  8. LYBALVI Cns $676 29 payments
  9. LYBALVI Cns $577 24 payments
  10. LYBALVI Cns $577 24 payments
  11. Other $9,197 463 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 65 drugs

Part D claims

6,417

Median for Nurse Practitioner: 389

Drug cost

$571,347

Median for Nurse Practitioner: $21,885

Branded share of claims

18%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 21 $177,188
Austedo Xr Deutetrabenazine Brand 14 $146,356
Rexulti Brexpiprazole Brand 24 $38,798
Vraylar Cariprazine Hcl Brand 26 $35,388
Caplyta Lumateperone Tosylate Brand 20 $31,574
Lurasidone Hcl Generic 64 $20,435
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 137 $11,804
Bupropion Xl Bupropion Hcl Brand 287 $9,701
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 251 $8,579
Aripiprazole Generic 214 $8,481

The 10 drugs with the highest cost, of 65 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$29,537

Medicare's payments for the services billed

Medicare patients

165

Average age 68

Services billed

606

119 women, 46 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 65%
Arthritis 55%
Diabetes 26%
Chronic kidney disease 22%
Ischemic heart disease 21%
COPD 19%
Heart failure 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 21 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
INGREZZA
  • Neurocrine Biosciences, Inc. $475
$475 21 —
Azstarys
  • Corium, Inc. $407
$407 — —
Qelbree
  • Supernus Pharmaceuticals, Inc. $393
$393 — —
VRAYLAR
  • AbbVie, Inc. $279
$279 26 —
CAPLYTA
  • ITI, Inc. $259
$259 20 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 21 in the dashboard with a free account

Records

750 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Tennessee

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record